A b s t r a c t
Immunophenotyping has a well-established role in the diagnosis and classification of non-Hodgkin lymphoma. The Revised European-American classification of lymphoid neoplasms 1 and the new World Health Organization 2 classification schemes for lymphoid neoplasms emphasized the importance of identifying distinct disease entities using a combination of clinical and laboratory findings. Immunophenotyping is recommended for the accurate distinction of lymphoid neoplasms displaying similar morphologic features. Once a diagnosis has been established, the presence of an abnormal phenotype can assist in the staging and detection of residual or relapsed disease. In addition to its use in diagnosis, immunophenotyping also is being applied to the selection of therapy for some patients with hematologic malignant neoplasms. The anti-CD20 monoclonal antibody rituximab is being used in the treatment of patients with relapsed or refractory, CD20+, low-grade lymphoma. 3 These clinical applications of immunophenotyping often are performed on the assumption that the phenotype remains stable over time and is uniform from one specimen to another. The present study was performed to determine the variability in expression of different lymphoid antigens in samples from patients with malignant lymphoma for whom more than 1 diagnostic specimen was evaluated by flow cytometry. We discuss the possible reasons for variability in antigen detection and/or expression and the usefulness of selected antibodies in lymphoma diagnosis. more than 1 sample was analyzed between January 1990 and December 2000 in the flow cytometry laboratory, University of Texas Health Science Center, San Antonio. We identified 211 specimens from 81 patients. Specimens included peripheral blood, bone marrow aspirate, body fluids, and lymphoid specimen biopsies including lymph node and spleen.
Two-color flow cytometric immunophenotyping was performed using a flow cytometer (FACScan, Becton Dickinson, San Jose, CA) by collecting ungated list-mode events. The forward-and side-scatter histograms were used to select the appropriate lymphocyte gate. The bone marrow specimens were processed using Histopaque-1077 (Sigma, St Louis, MO) for concentration of the mononuclear cells. The peripheral blood, body cavity fluids, and fine-needle aspirates were processed using RBC lysis. The lymphoid biopsy specimens were minced manually and teased in RPMI solution to release the mononuclear cells, followed by lysis of the RBC.
Cells were stained with fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled monoclonal antibodies using the following combinations: CD3 (FITC)/HLA-DR (PE), CD7 (FITC)/CD2 (PE), CD4 (FITC)/CD8 (PE), CD5 (FITC)/CD19 (PE), CD22 (FITC)/CD11c (PE), CD10 (FITC)/CD34 (PE), CD20 (FITC)/CD21 (PE), CD20 (FITC)/CD23 (PE), CD20 (FITC)/CD25 (PE), and kappa (FITC)/lambda (PE) (Becton Dickinson). The panel of antibodies varied slightly, with not all of the cases being analyzed for CD21 or CD23.
Analysis was performed using Simulset software (Becton Dickinson). A lymphoid gate was set using forward and side scatter. The position of histogram quadrant markers was determined using a combination of isotype controls and by visual inspection of dot plots for discrete populations of cells. The neoplastic population represented the majority of cells in most of the specimens analyzed. In these samples, an antigen was considered positive when it was expressed on at least 20% of the gated lymphocytes. In a few cases, the neoplastic cells represented the minority of cells analyzed. In these samples, the histograms were inspected visually for small but discrete populations of neoplastic cells. For these cases, the phenotype was reported as positive if the neoplastic cells expressed the antigen, even if the percentage of cells within the gate represented less than 20% of the total. Expression of an antigen was recorded as variable if it changed from positive to negative or negative to positive in at least 2 diagnostic samples received from the same patient. Histograms from apparently discrepant cases were reviewed to confirm that the staining pattern had changed and to evaluate the staining for possible technical artifact. Surgical pathology reports were reviewed in selected cases demonstrating phenotypic variability.
Results
We studied 211 specimens diagnostic for B-cell lymphoma from 81 patients. The change in antigen expression is summarized in ❚Table 1❚. Data for patients with variable expression of CD10, CD5, and CD23 are summarized in ❚Table 2❚, ❚Table 3❚, and ❚Table 4❚, respectively.
All cases (81) showed consistent expression of HLA-DR. Variable expression of CD19 was found in 3 cases and CD20 in 1 case of the 81 cases. Nine of 22 cases showed variability in CD21 expression, and 26 of 80 cases showed variability in CD22 expression. Variability in expression of CD19, CD20, CD21, and CD22 did not interfere with the diagnosis and appropriate classification of lymphoma. Six cases showed variable expression of CD10 (Table 2 ). This variability did not seem to interfere with the final diagnosis.
Variable expression of CD5 was identified in 2 cases (Table 3) . For case 72, the absence of expression of CD5 in the pleural fluid contributed to the difficulty establishing a firm diagnosis of lymphoma. ❚Figure 1❚ shows the CD19/CD5 and kappa/lambda histograms for the 2 specimens for case 74. The presence of CD5 coexpression on the cells from the second sample led to a workup for mantle cell lymphoma (MCL). A diagnosis of MCL was established following identification of cyclin D1 staining by paraffin section immunohistochemical analysis. A total of 29 cases had stable expression of CD5. In 10 of these cases, CD23 expression was not evaluated. In 15 cases, there was no change in CD23 expression. In 6 cases, the variability in expression of CD23 led to uncertainty about the subtype of lymphoma (Table 4) 
Discussion
In general, the phenotype of the cases analyzed correlated with the clinical manifestations and morphologic appearance. CD5 and CD23 were expressed in cases of small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). A large number of follicular lymphomas and some large cell lymphomas expressed CD10. Comparison of the phenotype obtained from analysis of multiple samples revealed some variability in the phenotype. Explanation for this variability includes true differences in the amount of antigen expressed and perceived differences owing to technical considerations.
Some antigens were highly conserved (CD5, CD10, CD19, CD20, and HLA-DR), whereas others were more variable (CD21, CD22, CD23, and CD25). Many of these phenotypic differences probably relate to the normal biology and function of the antigens. Both CD19 and CD20 are membrane-embedded molecules that have an essential role in cell maturation and function. The expression of CD19 is limited to B cells and dendritic cells. It is expressed in all stages of B-cell maturation. CD19 seems to have a role in antigen-specific responses by mature B cells. 4 The exact function of CD20 is not known. It seems to be involved in the regulation of activation, proliferation, and differentiation of B cells. 5 Although CD20 is expressed on both resting and activated B cells, its level of expression is more variable than CD19 and is increased following activation. The expression of CD21 by normal lymphoid cells is more variable than either CD19 or CD20. CD21 is lost from B cells during the early stages of activation and is absent from activated B cells expressing CD19 and CD20. 6 Therefore, although CD21 is present on most B-cell lymphoid neoplasms, its variable expression is not surprising. CD22 is a B cell, lineage-restricted, glycosylated, type I integral membrane protein. It is composed of an extracellular region and a cytoplasmic tail. It is likely that CD22 is an adhesion receptor that also functions as a signaling molecule during B-cell activation. The pattern of CD22 expression among B-cell neoplasms is heterogeneous and does not seem related to activation or differentiation. 7 Therefore, CD19 and CD20 are more sensitive indicators of a B-lymphocyte lineage than CD21 and CD22. CD20 expression has been reported on T lymphocytes and, therefore, is not entirely specific. 8 In addition to assigning lineage, flow cytometry also is used to identify a phenotype characteristic of a particular category of lymphoid malignant neoplasm. For example, CD5-expressing B-cell neoplasms include SLL and MCL. CD5 is a glycoprotein with structural features characteristic of a receptor molecule. Although its precise function is unknown, CD5 seems to modulate signaling through the antigen-specific receptor complex present on both T and B cells. CD5 is present throughout all stages of T-cell differentiation. 9 Although a large percentage of cord blood B lymphocytes express CD5, the number of CD5+ B lymphocytes drops during the first year of life and represents only a small proportion of B cells during adult life. 10 CD5 expression is used in the classification of small B-cell non-Hodgkin lymphomas. CD5 is expressed in most cases of CLL, SLL, and MCL. 11 In contrast, CD5 is expressed in only a minority of cases of prolymphocytic leukemia and plasmacytoid SLL. CD5 is typically absent from other lymphoid neoplasms, including hairy cell leukemia, follicular lymphoma, marginal zone lymphoma, large cell lymphoma, and Burkitt lymphoma. 11, 12 The expression of CD5, therefore, is valuable for determining the subtype of lymphoid neoplasm. 12 Variable expression of CD5 was identified in 2 cases. For 1 case (case 72), the absence of CD5 expression in the pleural fluid contributed to difficulty establishing a definitive diagnosis of lymphoma. For the other case (case 74), the differential diagnosis of CLL and MCL had to be resolved by immunohistochemical staining for cyclin D1.
CD10 has many known biologic functions. It is an enzyme that acts to reduce cellular responses to peptide hormones by regulating local peptide concentrations. 13 Although the function of CD10 in lymphocytes is not well defined, it seems to regulate B-cell development, either by directly or indirectly inactivating a peptide that stimulates Bcell growth and differentiation. CD10 is expressed in approximately 80% of follicular lymphomas, more than 90% of Burkitt lymphomas, and 30% of large cell lymphomas. 12, 14 Some of these large cell lymphomas probably represent transformed follicular lymphoma. CD10 usually is not expressed in SLL/CLL, MCL, lymphoplasmacytoid lymphoma, and marginal zone lymphoma. 14 Therefore, the presence of CD10 often helps establish the subtype of lymphoid malignant neoplasm, but its absence is less helpful. Variable expression of CD10 was identified in 6 cases. Alteration of the phenotype did not seem to alter the diagnosis.
CD 23 is a type II integral membrane glycoprotein. It is a B-cell activation antigen and a low-affinity receptor for IgE. CD23 expression on B cells is up-regulated after Epstein-Barr virus and interleukin-4 activation. The CD23 gene seems to be abnormally expressed and regulated in Bcell CLL. 15, 16 CD23 frequently is expressed by follicular lymphoma but is not expressed in MCL and marginal zone lymphoma. Therefore, the expression of CD23 alone is not helpful for distinguishing subtypes of lymphoma, but the presence of both CD5 and CD23 is valuable. MCL is CD5+ and CD23-, in contrast with SLL/CLL, which is CD5+ and CD23+. This distinction is important because although MCL and SLL/CLL can be morphologically similar, MCL has a more aggressive clinical course and a less favorable prognosis. 17 Variability in CD23 expression was identified in 14 cases. Five of these cases were CD5+, and the variable expression of CD23 led to doubt about the subtype of lymphoproliferative disorder.
In addition to true differences in antigen expression, the phenotype reported using flow cytometry is altered by changes in sample preparation, acquisition, and analysis. The instrument settings used at the time of acquisition have an important role in interpretation. One major source of variability is the process of compensation. Flow cytometry uses several fluorochromes in combination. Although the mean value of emission for each fluorochrome is different, there is some overlap between the emission spectra. To acquire accurate data, this spectrum overlap needs to be corrected (compensated for). Optimal compensation is a very important step in flow cytometry analysis, but, unfortunately, it is one of the most poorly understood concepts. Different software packages are available to assist in compensation, and these are frequently used in conjunction with beads labeled with fluorochromes with intensity similar to those of antibody-labeled cells. 18, 19 Although the labeled beads can be used to approximate the initial compensation settings, each specimen needs to be compensated individually. In most cases, a very precise compensation is not necessary since there is a clear separation between the positive and negative populations of cells. However, if an antigen is expressed only dimly and the sample has been overcompensated, it might be falsely interpreted as negative. On the other hand, a negative antigen can be falsely interpreted as positive if the specimen has been overcompensated. Inconsistent compensation is a possible reason for erroneous variability in phenotypes.
Another factor that can cause variability in the phenotype is the criteria used to determine when an antigen should be considered positive. 20 If the antigen is strongly expressed and a distinct population of cells is isolated, interpretation is easy. However, the analysis becomes more subjective if the neoplastic cells cannot be separated using gating, the antigen density is low, or both. An arbitrary 20% cutoff frequently has been used in the literature to distinguish antigen-positive tumors (antigen detected on 20% or more of the cells) from antigen-negative tumors (antigen detected on <20% of the cells). This criterion was appropriate for most of the cases in the study in which most cells analyzed were tumor cells. When tumor cells represented a small proportion of the total events analyzed and could not be isolated from normal cells, this criterion was not useful.
For the purposes of the study, the histograms were reviewed and the pattern of antigen expression compared from one case to another. A case was not identified as discrepant unless there had been a substantial change in the intensity of expression on the neoplastic cells. After reviewing these study cases, we decided to adopt a different, uniform, report format to facilitate interpretation and comparison of cases. For new clinical diagnoses, we recommend not reporting the percentage of expression of an antigen, but using a subjective determination about the presence or absence of an antigen, qualified by the intensity of expression (dim or bright). A more precise and accurate measurement of antigen expression can be accomplished using quantitative flow cytometry. 19 The use of quantitative flow cytometry permits estimating the number of antibodies bound per cell. However, this technique requires careful calibration of the instrument using standards such as lyophilized pellets of beads conjugated with different levels of a specific fluorochrome. Although quantitative flow cytometry has been used in research protocols, its value in clinical cytometry is questionable.
After reviewing a large number of flow cytometry histograms from patients with B-cell non-Hodgkin lymphoma, several conclusions can be drawn. The variability seen in the expression of a given antigen seems to bear some relationship to its function. CD19 and CD20 are important in the maturation of B cells, and, therefore, it is not surprising that their expression is stable. The activation antigens seem more variable in their expression. Lack of standardization of flow cytometry immunophenotyping procedures also can contribute to apparent discrepancies in phenotype.
